Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral vectors are highly safe and efficient gene delivery vehicles. However, numerous challenges in vector design remain, including neutralizing antibody responses, tissue transport and infection of resistant cell types. Changes must be made to the viral capsid to overcome these problems; however, very often insufficient information is available for rational design of improvements. We therefore applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of adeno-associated virus (AAV) 2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum. This approach, which can be extended to additional gene delivery challenges and serotypes, directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, directed evolution has been applied to generate AAV variants capable of evading neutralizing antibodies in vitro and in vivo.68–72”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“New AAV variants created through directed evolution withstood up to 35-fold higher in vitro concentrations of pooled human antibodies than AAV2.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“These antibody neutralization properties also led to enhanced transduction in vivo, where AAV variants were capable of significantly higher transduction in the liver, heart and muscle than AAV2 in mice passively immunized with human antibodies.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“Compared with natural variants, the engineered AAV-DJ variant, consisting of residues from AAV2, AAV8, and AAV9 variants, has been shown to transduce hepatocytes in the presence of human intravenous IgG [194, 195].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [194]
In the citing paper
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [88]
Citations
Cites
Rapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo
Lai, K., Kaspar, B. K., Gage, F. H., & Schaffer, D. V. (2003) · Nature Neuroscience · doi:10.1038/nn983 · Cited by 799
Self-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Cited by
Items 201–300 of 535
Optimizing bacteriophage engineering through an accelerated evolution platform
Favor, A. H., Llanos, C. P., Youngblut, M. D., & Bardales, J. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-70841-1 · Cited by 51
Vector engineering, strategies and targets in cancer gene therapy
Singh, V., Khan, N., & Jayandharan, G. R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00331-7 · Cited by 56
“The library thus created is then subjected to multiple rounds of selective pressure to screen for vectors with the desired property or function [75, 76].”
BackgroundOptimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes
Maersch, S., Huber, A., Büning, H., Hallek, M., & Perabo, L. (2010) · Virology · doi:10.1016/j.virol.2009.10.021 · Cited by 50
Directed evolution of adeno-associated virus for glioma cell transduction
Maguire, C. A., Gianni, D., Meijer, D. H., Shaket, L. A., Wakimoto, H., Rabkin, S. D., Gao, G., & Sena-Esteves, M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9972-7 · Cited by 50
“Since AAV2 transduces U87 cells efficiently (*100% of cells transduced at 10(4) gc/cell), a DNA shuffled library created by error-prone PCR based on AAV2 may be one way to increase transduction of this particular cell type by an even greater fold [19].”
BackgroundIntravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System
Gessler, D. J., Tai, P. W. L., Li, J., & Gao, G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_8 · Cited by 57
Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond
Valdmanis, P. N., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.171 · Cited by 58
Wagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 54
Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
Li, C., Wu, S., Albright, B., Hirsch, M., Li, W., Tseng, Y.-S., Agbandje-McKenna, M., McPhee, S., Asokan, A., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.134 · Cited by 48
Han, Z., Luo, N., Ma, W., Liu, X., Cai, Y., Kou, J., Wang, J., Li, L., Peng, S., Xu, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39554-7 · Cited by 53
Cabanes‐Creus, M., Westhaus, A., Navarro, R. G., Baltazar, G., Zhu, E., Amaya, A. K., Liao, S. H. Y., Scott, S., Sallard, E., Dilworth, K. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.004 · Cited by 45
“AAV2-T503A has been previously shown to improve in vitro transduction when compared to AAV2,(59) while AAV2-N596D was reported as a heparin-de-targeted variant.(60) Nevertheless, the synergestic effect of the combined amino acid substitutions on human liver transduction has gone unrecognized.”
BackgroundAAV-Containing Exosomes as a Novel Vector for Improved Gene Delivery to Lung Cancer Cells
Liu, B., Li, Z., Huang, S. W., Yan, B., He, S., Chen, F., & Liang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707607 · Cited by 54
Treweek, J. B., & Gradinaru, V. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.03.012 · Cited by 46
Bass-Stringer, S., Bernardo, B. C., May, C. N., Thomas, C. J., Weeks, K. L., & McMullen, J. R. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.03.005 · Cited by 50
Lochrie, M. A., Tatsuno, G. P., Arbetman, A. E., Jones, K., Pater, C., Smith, P. H., McDonnell, J. W., Zhou, S., Kachi, S., Kachi, M., et al. (2006) · Virology · doi:10.1016/j.virol.2006.05.023 · Cited by 48
Strategies for targeting primate neural circuits with viral vectors
El-Shamayleh, Y., Ni, A. M., & Horwitz, G. D. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00087.2016 · Cited by 52
Conformal prediction under feedback covariate shift for biomolecular design
Fannjiang, C., Bates, S., Angelopoulos, A. N., Listgarten, J., & Jordan, M. I. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204569119 · Cited by 128
“As such, the proteins that constitute the capsid have been modified to enhance various fitness functions, such as the ability to enter specific cell types and evade the immune system [37, 15, 58].”
Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy
Sen, D., Balakrishnan, B., Gabriel, N., Agrawal, P., Roshini, V., Samuel, R., Srivastava, A., & Jayandharan, G. R. (2013) · Scientific Reports · doi:10.1038/srep01832 · Cited by 44
Engineering viral vectors for acoustically targeted gene delivery
Li, H., Harb, M., Heath, J. E., Trippett, J. S., Shapiro, M. G., & Szablowski, J. O. (2024) · Nature Communications · doi:10.1038/s41467-024-48974-y · Cited by 55
“Capsid engineering techniques 27 in which mutations are introduced into viral capsid proteins have been used to enhance gene delivery properties such as tissue speci fi city 5,6,28 – 30 , immune evasion 31 , or axonal tracing 32 .”
MethodChoi, D. S., Jin, H., Yoo, S. Y., & Lee, S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4003234 · Cited by 47
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
“49 For instance, directed evolution has been an efficient approach to derive tissue tropisms in induced pluripotent stem cells (iPSCs) 50 and human ciliated airway epithelium.”
Yuan, Z., Qiao, C., Hu, P., Li, J., & Xiao, X. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.241 · Cited by 42
“, 2002), direct evolution of tissue-tropic AAV capsids (Maheshri et al., 2006; Li et al., 2008; Yang et al., 2009; Asokan et al., 2010), and double-stranded AAV vectors (McCarty et al.”
BackgroundEfficacy of Codelivery of Dual AAV2/5 Vectors in the Murine Retina and Hippocampus
Palfi, A., Chadderton, N., McKee, A. G., Blanco Fernandez, A., Humphries, P., Kenna, P. F., & Farrar, G. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.142 · Cited by 42
“, 2005) and engineered AAV capsid serotypes (Maheshri et al., 2006; Li et al., 2008).”
Advances in Cell and Gene-based Therapies for Cystic Fibrosis Lung Disease
Oakland, M., Sinn, P. L., & McCray, P. B. (2012) · Molecular Therapy · doi:10.1038/mt.2012.32 · Cited by 51
The structure of AAVrh32.33, a novel gene delivery vector
Mikals, K., Nam, H.-J., Van Vliet, K., Vandenberghe, L. H., Mays, L. E., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.03.020 · Cited by 41
“Thus significant effort is being extended to identify AAV vectors with a low immune prevalence in the human population and to understanding the antigenic structure of the capsid epitopes towards elucidating the epitopes to which these responses are directed (Gurda et al., 2012, 2013; Huttner et al., 2003; Lochrie et a…”
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
“The best variants identified in this screen had 10 to 100 fold higher resistance to neutralizing antibodies.(103) Another study used the capsid shuffling method (wherein the capsid sequences of known AAVs are fragmented and reassembled to generate variant sequences) to generate AAV variants library and screen these to…”
BackgroundA Robust and All-Inclusive Pipeline for Shuffling of Adeno-Associated Viruses
Herrmann, A.-K., Bender, C., Kienle, E., Große, S., Andari, J. E., Botta, J., Schürmann, N., Wiedtke, E., Niopek, D., & Grimm, D. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00373 · Cited by 40
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective
Hayward, C., Banner, N. R., Morley-Smith, A. C., Lyon, A. R., & Harding, S. E. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.018 · Cited by 43
“Some of these strategies are in the realm of viral engineering to alter known antigenic regions of the AAV, 84 or by selecting AAV variants with increased resistance to neutralizing antibodies, 85 or a combination of both strategies.”
An Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy
Asokan, A., & Samulski, R. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2515 · Cited by 38
“4, both of which contain mutations at critical antigenic sites, thereby capable of evading neutralizing antibodies in human serum (Maheshri et al., 2006).”
BackgroundHwang, J.-H., Lee, S., Kim, E., Kim, J., Lee, C., Ahn, I., & Jang, J. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.10.019 · Cited by 40
“45), CMV GFP vector plasid containing ITR (pAAV CMV GFP SN), and an adenoviral helper lasmid (Stratagene), were transfected via calcium phosphate into AV 293 cells (Maheshri et al., 2006). The resulting viral vectors ere harvested as previously described (Koerber et al., 2006) and Pharmaceutics 421 (2011) 397– 404”
MethodAAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
The ice age – A review on formulation of Adeno-associated virus therapeutics
Grossen, P., Skaripa-Koukelli, I., van Haasteren, J., Machado, A. H. E., & Dürr, C. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.07.002 · Cited by 43
AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects
Chwalenia, K., Feng, V.-Y., Hemmer, N., Friedrichsen, H. J., Vorobieva, I., Wood, M. J. A., & Roberts, T. C. (2025) · Gene Therapy · doi:10.1038/s41434-025-00561-6 · Cited by 44
“15 and 2.4 vectors were designed to evade NAbs in vitro and in vivo in mice without affecting the tropism [178].”
InfluentialWang, Y., Ling, C., Song, L., Wang, L., Aslanidi, G. V., Tan, M., Ling, C., & Srivastava, A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.090 · Cited by 37
“In addition, new technologies have also been developed to generate capsid gene libraries through error-prone PCR (Maheshri et al., 2006) and DNA shuffling (Li et al.”
Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery
Gonzalez, T. J., Mitchell-Dick, A., Blondel, L. O., Fanous, M. M., Hull, J. A., Oh, D. K., Møller-Tank, S., Rivera, R. M. C., Piedrahita, J. A., & Asokan, A. (2023) · Nature Protocols · doi:10.1038/s41596-023-00875-y · Cited by 42
Kohlbrenner, E., Henckaerts, E., Rapti, K., Gordon, R. E., Linden, R. M., Hajjar, R. J., & Weber, T. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.049 · Cited by 36
“…will eventually become commercially available, much work is currently being done in engineering the viral capsid to create novel mutant and chimeric AAVs that, for instance, target specific tissues (Asokan et al., 2012) or show improved resistance to neutralizing antibodies (Maheshri et al., 2006).”
BackgroundGene Delivery Strategies to Promote Spinal Cord Repair: Supplementary Issue: Stem Cell Biology
Walthers, C. M., & Seidlits, S. K. (2015) · Biomarker Insights · doi:10.4137/bmi.s20063 · Cited by 37
Qian, R., Xiao, B., Li, J., & Xiao, X. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.010 · Cited by 37
“Molecular previously described by Maheshri et al.(22) in which error prone PCR (EPPCR) and staggered extension protocol (stEP) generated random point mutations in the AAV5 VP3 gene.”
MethodLong Noncoding RNAs as Therapeutic Targets
Pierce, J. B., Zhou, H., Simion, V., & Feinberg, M. W. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-92034-0_9 · Cited by 41
Zhao, Z., Kim, J., Suja, V. C., Kapate, N., Gao, Y., Guo, J., Muzykantov, V. R., & Mitragotri, S. (2022) · Advanced Science · doi:10.1002/advs.202201293 · Cited by 36
Magnetically enhanced adeno-associated viral vector delivery for human neural stem cell infection
Kim, E., Oh, J. S., Ahn, I., Park, K. I., & Jang, J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.075 · Cited by 38
Ho, M. L., Adler, B. A., Torre, M. L., Silberg, J. J., & Suh, J. (2013) · ACS Synthetic Biology · doi:10.1021/sb400076r · Cited by 36
Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors
Seto, J. T., Ramos, J. N., Muir, L. A., Chamberlain, J. S., & Odom, G. L. (2012) · Current Gene Therapy · doi:10.2174/156652312800840603 · Cited by 43
Gene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Gene regulation technologies for gene and cell therapy
Butterfield, G. L., Reisman, S. J., Iglesias, N., & Gersbach, C. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.004 · Cited by 47
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Library Generation by Gene Shuffling
Meyer, A. J., Ellefson, J. W., & Ellington, A. D. (2014) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1512s105 · Cited by 34
“…directed evolution of enzyme function, such as the ability to work at higher temperatures (Giver et al., 1998) or recognize new substrates (Brühlmann and Chen, 1999) and of viral coat proteins that expand host range (Pekrun et al., 2002) and enable enhanced gene delivery (Maheshri et al., 2006).”
BackgroundChapman, M. S., Trzynka, A., & Chapman, B. K. (2013) · Journal of Structural Biology · doi:10.1016/j.jsb.2013.01.003 · Cited by 34
“is being used to overcome this limitation, introducing genetic variation by random DNA shuffling between different AAVs, then selecting and cloning variants with the desired properties (Koerber et al., 2008; Maheshri et al., 2006).”
MethodA top-down approach for construction of hybrid polymer-virus gene delivery vectors
Ramsey, J. D., Vu, H. N., & Pack, D. W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.031 · Cited by 39
Vectored antibody gene delivery for the prevention or treatment of HIV infection
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000145 · Cited by 37
High-Throughput Dissection of AAV–Host Interactions: The Fast and the Curious
Herrmann, A.-K., & Grimm, D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.022 · Cited by 38
Curative Cell and Gene Therapy for Osteogenesis Imperfecta
Schindeler, A., Lee, L. R., O’Donohue, A. K., Ginn, S. L., & Munns, C. F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4549 · Cited by 44
“For AAVs, it was first used to generate recombinant AAV2 (rAAV2) vectors, which were not targeted by neutralizing antibodies in vivo, and vectors that had altered affinities for heparin.((83)) Capsid engineering is a different approach that involves generating hybrid capsids with novel targeting capabilities.”
MethodSystemic scAAV9 variant mediates brain transduction in newborn rhesus macaques
Dehay, B., Dalkara, D., Doveró, S., Li, Q., & Bézard, E. (2012) · Scientific Reports · doi:10.1038/srep00253 · Cited by 40
“Additionally, other viral engineering approaches can be used to further enhance the transduction capabilities of AAV in this contex”
BackgroundEnhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant
Kotterman, M. A., Vazin, T., & Schaffer, D. V. (2015) · Development · doi:10.1242/dev.115253 · Cited by 36
“…protein (GFP) or CA β-catenin under the control of a CMV promoter were packaged in HEK293T cells using the calcium phosphate transfection method as described, and the viruses were purified by iodixonal gradient centrifugation and Amicon filtration (Excoffon et al., 2009; Maheshri et al., 2006).”
BackgroundMethodInfluentialSelf-citationStructure comparison of the chimeric AAV2.7m8 vector with parental AAV2
Bennett, A., Keravala, A., Makal, V., Kurian, J., Belbellaa, B., Aeran, R., Tseng, Y.-S., Sousa, D., Spear, J., Gasmi, M., et al. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2019.107433 · Cited by 33
Quantitative 3D Tracing of Gene-delivery Viral Vectors in Human Cells and Animal Tissues
Xiao, P.-J., Li, C., Neumann, A., & Samulski, R. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.250 · Cited by 33
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 36
“25,26 While not the subject of this review, recombinant AAV vectors can be produced and purified at scale based on their physical properties using ion exchange, or affinity chromatography, and/or density gradient ultracentrifugation.”
BackgroundZhou, X., Liu, J., Xiao, S., Liang, X., Li, Y., Mo, F., Xin, X., Yang, Y., & Gao, C. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s459905 · Cited by 34
“Rational design 59–61 Tropism and immune evasion Lack of diverse mutants Directed evolution 62 Do not need to know its structure and properties Time-consuming because of many variants In silico design 63,64 Make more effective and in-depth research on undeveloped AAV sequences”
BackgroundViral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease
Tang, Y., Yan, Z., & Engelhardt, J. F. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.013 · Cited by 37
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System
Tan, J.-K. Y., Sellers, D., Pham, B., Pun, S., & Horner, P. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00108 · Cited by 26
“Thus, several lab have begun to systematically mutate adeno-associated vectors in order to expand their clinical application and increase delivery into the CNS (Maheshri et al., 2006; Kotterman and Schaffer, 2014), innovative strategies have been adopted to utilize retrograde axonal transport to deliver biologics into…”
MethodArtificial Intelligence‐Based Approaches for AAV Vector Engineering
Tan, F., Dong, Y., Qi, J., Yu, W., & Chai, R. (2025) · Advanced Science · doi:10.1002/advs.202411062 · Cited by 43
Cystic fibrosis gene therapy: successes, failures and hopes for the future
Griesenbach, U., & Alton, E. W. F. W. (2009) · Expert Review of Respiratory Medicine · doi:10.1586/ers.09.25 · Cited by 38
AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model
Verhelle, A., Nair, N., Everaert, I., Overbeke, W. V., Supply, L., Zwaenepoel, O., Peleman, C., Dorpe, J. V., Lahoutte, T., Devoogdt, N., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx056 · Cited by 34
Battling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches
Mijanović, O., Branković, A., Borovjagin, A. V., Butnaru, D., Bezrukov, E., Sukhanov, R., Shpichka, A., Timashev, P., & Ulasov, I. (2020) · Viruses · doi:10.3390/v12040460 · Cited by 24
“insertion into known sites of AAV capsid [88,89] or phage display [90] and ultimately involves a selection process that requires multiple generations of screening to identify functional capsids.”
BackgroundHigh Capsid–Genome Correlation Facilitates Creation of AAV Libraries for Directed Evolution
Nonnenmacher, M., van Bakel, H., Hajjar, R. J., & Weber, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.3 · Cited by 32
Kienle, E., Senís, E., Börner, K., Niopek, D., Wiedtke, E., Große, S., & Grimm, D. (2012) · Journal of Visualized Experiments · doi:10.3791/3819 · Cited by 31
Directed adenovirus evolution using engineered mutator viral polymerases
Uil, T. G., Vellinga, J., de Vrij, J., van den Hengel, S. K., Rabelink, M. J. W. E., Cramer, S. J., Eekels, J. J. M., Ariyürek, Y., van Galen, M., & Hoeben, R. C. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1258 · Cited by 32
“However, the usefulness of the latter of these methods for Ad engineering has—in comparison to that for AAV (68) or retrovirus (69) engineering—been limited due to the difficulty of generating sufficiently complex adenoviral libraries.”
BackgroundVliet, K. V., Mohiuddin, Y., McClung, S. H., Blouin, V., Rolling, F., Moullier, P., Agbandje‐McKenna, M., & Snyder, R. O. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.03.020 · Cited by 35
“A directed evolution approach for high throughput selection of customized rAAV vectors with enhanced properties has been shown to generate vectors with altered affinities for heparin or the ability to evade neutralizing antibodies (Maheshri et al., 2006).”
BackgroundSelot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“[46] have reported combination of DNA shuffling and error-prone PCR mutagenesis strategy for directed evolution of AAV capsid.”
Dickey, D. D., Excoffon, K. J. D. A., Koerber, J. T., Bergen, J., Steines, B. R., Klesney‐Tait, J., Schaffer, D. V., & Zabner, J. (2011) · Journal of Virology · doi:10.1128/jvi.05154-11 · Cited by 32
“Directed evolution strategies have proven to be a powerful tool for gaining insight into the biology of AAV and for generating novel AAV capsids with enhanced infectivity and tissue and cell-specific targeting (8, 17, 19).”
Self-citationLiver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
Bian, H., Wilden, H., Fournier, P., Peeters, B. P. H., & Schirrmacher, V. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.6.1359 · Cited by 35
Directed evolution for drug and nucleic acid delivery
Hida, K., Hanes, J. S., & Ostermeier, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.022 · Cited by 36
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Fakhiri, J., & Grimm, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.005 · Cited by 30
Strategies to improve safety profile of AAV vectors
Suoranta, T., Laham-Karam, N., & Ylä‐Herttuala, S. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1054069 · Cited by 33
“- Classical pathway: engineering to eliminate anticapsid antibody epitopes (Maheshri et al., 2006; Perabo et al., 2006; Bartel et al., 2012) - Minimising overall vector immunogenicity (Colella et al.”
BackgroundA viral over-expression system for the major malaria mosquito Anopheles gambiae
Suzuki, Y., Niu, G., Hughes, G. L., & Rasgon, J. L. (2014) · Scientific Reports · doi:10.1038/srep05127 · Cited by 31
Ran, G., Chen, X., Xie, Y., Zheng, Q., Xie, J., Yu, C., Pittman, N., Qi, S., Yu, F., Agbandje‐McKenna, M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.007 · Cited by 29
“Efforts are currently ongoing in a number of laboratories, including our own, to achieve high-efficiency transduction at reduced vector doses, which include the following: (1) use of rAAV vectors with a natural tropism for the target cell/tissue/organ;(3) (2) rational design of viral capsid proteins with site-directed…”
BackgroundGenome-wide activation screens to increase adeno-associated virus production
Barnes, C. R., Lee, H., Ojala, D. S., Lewis, K. K., Limsirichai, P., & Schaffer, D. V. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.026 · Cited by 31
“These vectors were packaged in HEK293T cells as previously described.(49,50)”
Self-citationRegenerative nanomedicine and the treatment of degenerative retinal diseases
Zarbin, M. A., Montemagno, C. D., Leary, J. F., & Ritch, R. H. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.167 · Cited by 29
Engineered bacteriophages: A panacea against pathogenic and drug resistant bacteria
Kakkar, A., Kandwal, G., Nayak, T., Jaiswal, L. K., Srivastava, A., & Gupta, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34333 · Cited by 31
“Chemically accelerated viral evolution (CAVE) is based on a directed evolutionary strategy in which phages undergo a series of chemical mutagenesis cycles to evolve with better functional characteristics than the original wild-type form [57].”
BackgroundAAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 32
“It starts with generating mutations in the capsid by site-directed mutagenesis or high-throughput approaches, then selecting the variants with the ability to evade neutralizing antibodies in the presence of anti-AAV serum [139-141].”
BackgroundImproving clinical efficacy of adeno associated vectors by rational capsid bioengineering
Sen, D. (2014) · Journal of Biomedical Science · doi:10.1186/s12929-014-0103-1 · Cited by 32
“, [65] utilized directed evolution approach to generate AAV with enhanced gene delivery capability.”
Chai, Z., Sun, J., Rigsbee, K. M., Wang, M., Samulski, R. J., & Li, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.005 · Cited by 27
“Other approaches to select AAV variants through error-prone PCR or a DNA shuffling library might be able to enhance transduction efficiency [23,44,45] or to escape pre-existing antibodies [21,46].”
BackgroundKim, M.-A., Ryu, N., Kim, H.-M., Kim, Y., Lee, B., Kwon, T.-J., Bok, J., & Kim, U. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.002 · Cited by 29
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 30
“opment of further library types such as those consisting of shuffled capsids [98] or capsids with loop replacements [99] or with point mutations introduced by error-prone (EP) polymerases [100,101].”
BackgroundLibrary Selection and Directed Evolution Approaches to Engineering Targeted Viral Vectors
Jang, J., Lim, K., & Schaffer, D. V. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21541 · Cited by 26
“…to the viral envelope (Benedict et al., 1999; Cosset et al., 1995; Russell et al., 1993), as well as non-covalent attachment of adaptor molecules composed of the viral receptor fused to a targeting ligand (Snitkovsky and Young, 1998), have been employed to target retroviruses to new receptors.”
BackgroundMethodSelf-citationKellish, P. C., Marsic, D., Crosson, S. M., Choudhury, S., Scalabrino, M. L., Strang, C. E., Hill, J. L., McCullough, K. T., Peterson, J. J., Fajardo, D. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.001 · Cited by 28
Mechanisms and Delivery of tRNA Therapeutics
Ward, C., Beharry, A., Tennakoon, R., Rozik, P., Wilhelm, S. D. P., Heinemann, I. U., & O’Donoghue, P. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00142 · Cited by 26
Studying ALS: Current Approaches, Effect on Potential Treatment Strategy
Ustyantseva, E., Medvedev, S. P., & Zakian, S. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41283-8_11 · Cited by 28
Viral vector‐based cancer treatment and current clinical applications
Xie, L., Han, Y., Liu, Y., Zhou, Y., Yu, J., von Brunn, A., & Lei, J. (2023) · MedComm – Oncology · doi:10.1002/mog2.55 · Cited by 29
Novel GP64 envelope variants for improved delivery to human airway epithelial cells
Sinn, P. L., Hwang, B.-Y., Li, N., Ortiz, J. L. S., Shirazi, E., Parekh, K. R., Cooney, A. L., Schaffer, D. V., & McCray, P. B. (2017) · Gene Therapy · doi:10.1038/gt.2017.78 · Cited by 25
Self-citationCRISPR/Cas therapeutic strategies for autosomal dominant disorders
Caruso, S. M., Quinn, P. M. J., da Costa, B. L., & Tsang, S. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158287 · Cited by 29
Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases
Lin, C., Greenblatt, M. B., Gao, G., & Shim, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.022 · Cited by 25
“73,74 Along with barcoding transgenes to allow for the iterative enrichment of candidates, next-generation sequencing analysis has simpli fi ed the discovery of novel vector capsids.”
Kim, J.-S., Chu, H. S., Park, K., Won, J.-I., & Jang, J.-H. (2011) · Gene Therapy · doi:10.1038/gt.2011.84 · Cited by 26
Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors
Ji, J., Lefebvre, E., & Laporte, J. (2024) · Skeletal Muscle · doi:10.1186/s13395-024-00341-7 · Cited by 29
“…approaches were followed: rational design modification of the capsid through insertion of a peptide sequence presenting high affinity for a known surface receptor [18–21], and directed evolution through the introduction of random capsid mutations and several rounds of in vivo selection [22–26].”
MethodBioreducible Polypeptide Containing Cell-Penetrating Sequence for Efficient Gene Delivery
Chen, S., Han, K., Yang, J., Lei, Q., Zhuo, R., & Zhang, X. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1040-5 · Cited by 24
Gene therapy for the neurological manifestations in lysosomal storage disorders
Cheng, S. H. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r047175 · Cited by 25
Metadata
- Authors
- Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Abigail Wexner Research Institute (US)
- Corresponding author
- Schaffer, David V
- Venue
- Nature Biotechnology
- Published
- 2006-01-22
- Volume
- 24
- Issue
- 2
- Pages
- 198-204
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2102111681
- Cited by
- 538
- References
- 53
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 29 · 2023: 31 · 2022: 31 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 19 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 32 · 2013: 31 · 2012: 23
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- ALS Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV2, directed evolution, viral capsid, gene delivery vectors, heparin binding, antibody neutralization, high-throughput selection
- MeSH terms
- Adenoviridae, Genetic Vectors, Transfection, Genetic Therapy, Drug Delivery Systems, Gene Targeting, Directed Molecular Evolution, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.